Pharmacologic Strategies for the Etonogestrel Implant in HIV-Infected Women
Status:
Active, not recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the frequency of ovulation and cervical mucus quality of
HIV-infected women on efavirenz (EFV)-based antiretroviral therapy (ART) using either a
single etonogestrel (ENG) implant or two ENG implants for at least one year.
Phase:
Phase 2
Details
Lead Sponsor:
Catherine Chappell University of Pittsburgh
Collaborators:
Infectious Disease Institute, Kampala, Uganda University of Nebraska